Atlas Trials

Safety & Immunogenicity of RVM-V001/RVM-V002 or RVMV001+RVMV002 (Co Administered as Separate Injections) in Healthy Individuals

Clinical trial NCT05788185 · TERMINATED

Trial details

NCT number
NCT05788185
Sponsor
RVAC Medicines (US), Inc.
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Infectious DiseaseCOVID-19
Start date
2023-03-22
Primary completion
2023-09-21
Enrollment
24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.